Inhibition of serotonin transporters disrupts the enhancement of fear memory extinction by 3,4-methylenedioxymethamphetamine (MDMA)

For several decades MDMA has been investigated as an adjunct to psychotherapy because of acute mood-elevating and prosocial effects, and recent clinical work has reported long-term reductions in PTSD symptoms after only two MDMA-assisted psychotherapy sessions. Young and colleagues note that preclinical studies suggest MDMA enhances the extinction of fear memory, a learning process central to exposure-based therapies for PTSD, but that the pharmacological and psychological mechanisms underlying this effect remain incompletely understood. The introduction frames fear extinction as a targetable process where pharmacological adjuncts could improve exposure therapy outcomes, and highlights the need to characterise the monoaminergic mechanisms through which MDMA influences extinction before broader clinical application, especially because many PTSD patients are commonly treated with SSRIs. This study set out to identify which monoamine transporters and receptor mechanisms are required for MDMA's enhancement of fear memory extinction. Using auditory Pavlovian fear conditioning in mice, the investigators compared two behavioural readouts—conditioned freezing (a common rodent index) and fear‑potentiated startle (FPS, a cross‑species measure more directly comparable to human studies)—and tested whether pharmacological inhibition of serotonin (5-HT), norepinephrine (NE) or dopamine (DA) transporters, as well as manipulation of 5-HT2A receptors, alters MDMA's extinction‑enhancing effects.

Young and colleagues used male C57BL/6 mice (postnatal days 49–112) housed under standard conditions and tested during the lights-on phase. Drugs included racemic MDMA, the selective 5-HT2A antagonist M100907 (M100), the SSRI citalopram, the NRI reboxetine, the DAT inhibitor RTI-336, the 5-HT2A agonist DOI, and the 5-HT releaser fenfluramine. All compounds were administered intraperitoneally (10 μL/g) and timing was chosen so transporter inhibitors reached peak brain levels 30 min before MDMA, which itself was given 30 min before behavioural procedures. Conditioned freezing experiments used a three-day protocol: cued fear conditioning (four CS–US pairings) on day 1, sub-optimal extinction training (16 CS presentations in a novel context) on day 3 with MDMA or saline given 30 min beforehand, and extinction testing on day 4. For chronic SSRI experiments, mice received daily citalopram (10 mg/kg, i.p.) for 22 days between conditioning and extinction, with extinction training 48 h after the final injection. Freezing was recorded and scored with video tracking software. Two separate FPS experiments were conducted in startle chambers. The first established a dose–response for MDMA on within‑ and between‑session extinction: acclimation and pre‑test sessions preceded fear conditioning (10 CS–US pairings), a memory test, and then extinction training with MDMA or vehicle administered 20–30 min prior to placement in the chamber. The second FPS experiment followed an analogous timeline but tested the impact of 22 days of chronic citalopram treatment on MDMA's effects. Startle amplitudes and FPS calculations were derived from averaged startle responses across trials. Statistical analyses employed two‑tailed t tests, one‑ or two‑way ANOVAs, and repeated‑measures ANOVAs with α = 0.05. Post hoc comparisons used Dunnett's test for dose–response data and Bonferroni correction for other comparisons. The investigators report assessing homogeneity of variance with Bartlett's test and present data as mean ± SE.

MDMA enhanced the lasting extinction of conditioned freezing and of FPS in these paradigms. In dose‑finding for transporter inhibitors, only 20 mg/kg citalopram reduced conditioned freezing during extinction training, so 10 mg/kg of citalopram, reboxetine and RTI-336 (a selective DAT blocker) were used in subsequent experiments because this dose did not significantly affect extinction when given alone. When mice were pre-treated acutely with transporter inhibitors before MDMA and extinction training, a main effect of MDMA on reducing conditioned freezing was observed across groups. RTI-336 produced a main effect on conditioned freezing but did not prevent MDMA from reducing freezing. By contrast, post hoc comparisons indicate that MDMA’s reductions in freezing seen with vehicle pre-treatment were prevented when mice received citalopram prior to MDMA (post hoc p > 0.99) and were attenuated with reboxetine pre-treatment (p = 0.08), although interaction terms reported for citalopram and reboxetine did not reach significance. Only mice pre-treated with citalopram prior to MDMA exhibited significantly greater conditioned freezing than vehicle‑pretreated mice that received MDMA (p < 0.001). Chronic daily citalopram (10 mg/kg for 22 days) abolished MDMA's extinction‑enhancing effects on conditioned freezing even when extinction training occurred 48 h after the final SSRI injection. During extinction training MDMA-treated mice previously given vehicle showed reduced freezing during early CS presentations; this benefit was lost after chronic citalopram (one‑way ANOVAs and interaction effects reported, n = 10/group). Similar blocking of MDMA’s effect was seen during extinction testing the following day. In contrast, a single citalopram dose given 24 h before extinction did not prevent MDMA’s persistent reductions in freezing, arguing against simple drug carryover as the explanation for the chronic effect. Fenfluramine, a selective 5-HT releaser via the 5-HTT, dose‑dependently increased conditioned freezing during extinction training but did not produce lasting extinction when animals were retested the next day. To probe 5-HT2A receptor involvement, mice chronically treated with citalopram exhibited significantly reduced DOI‑induced head‑twitch behaviour (a 5-HT2A‑mediated response), indicating downregulated 5-HT2A function after chronic SSRI. Pre-treatment with the selective 5-HT2A antagonist M100 (0.6 mg/kg) obstructed MDMA’s reduction of conditioned freezing during extinction training and attenuated MDMA's effect on conditioned freezing 24 h later. Regarding FPS, the extracted text reports that chronic citalopram did not alter FPS induced by four CS presentations during a brief memory test, and that MDMA (7.8 mg/kg) given prior to extinction training significantly reduced FPS the following day regardless of whether mice had been chronically treated with citalopram or vehicle. The extraction ends abruptly for this experiment, and the text does not clearly report whether chronic or acute 5-HTT inhibition reliably blocked MDMA’s effect on FPS across all analyses in this manuscript.

Young and colleagues interpret these findings as supporting the hypothesis that MDMA enhances fear memory extinction and that serotonergic mechanisms—specifically access to the serotonin transporter (5-HTT) and signalling at 5-HT2A receptors—are important for that effect. They note that MDMA reduced both conditioned freezing and FPS when administered before extinction training, and that validation of the FPS effect is particularly relevant because FPS is commonly used in human studies of conditioned fear. The authors emphasise that increasing extracellular 5-HT per se is unlikely to account for MDMA’s extinction enhancement: neither acute nor chronic citalopram alone improved extinction, and fenfluramine (a selective 5-HT releaser) failed to yield lasting extinction benefits despite transiently increasing freezing during training. Instead, they propose that MDMA’s effect depends on more complex pharmacodynamics that require transporter‑mediated access and subsequent downstream signalling, including activation of 5-HT2A receptors. Supporting this, chronic SSRI treatment reduced DOI‑induced 5-HT2A‑mediated head‑twitches and the 5-HT2A antagonist M100 blocked MDMA’s extinction enhancement. Alternate monoaminergic contributions are discussed: MDMA also elevates NE and DA and interacts with adrenergic and dopaminergic systems relevant to extinction, but in this study reboxetine (NET inhibitor) and RTI-336 (DAT inhibitor) did not reproduce the blockade seen with 5-HTT inhibition. The authors therefore suggest indirect pathways—such as 5-HT2A‑mediated facilitation of DA release or involvement of D2 receptors—could contribute to MDMA’s net effect. Key limitations acknowledged by the investigators include uncertainty about the precise mechanisms by which acute and chronic SSRI treatments block MDMA’s effect (for example, rapid 5-HT‑induced desensitisation of 5-HT2A receptors after acute SSRI versus downregulation of 5-HTT and 5-HT2A with chronic SSRI), and the incomplete picture regarding FPS interactions because the extracted results are partial. They also recognise that extinction expression during the acute drug session does not necessarily predict lasting extinction outcomes, and that MDMA's acute stimulant or anxiogenic actions may transiently mask or alter fear expression independently of extinction learning. In translational terms, the authors highlight that concurrent SSRI treatment—common in PTSD patients—could obstruct MDMA's beneficial effects on extinction and thus deserves careful consideration in clinical research of MDMA‑assisted exposure therapies. They suggest that MDMA may still be a useful adjunct for treatment‑resistant patients but stress the caveat that SSRI co‑administration may limit efficacy and should be investigated further.